Nasus Pharma Ltd (NSRX) company profile
Close on Nov 17, 2026Market cap $23.53MP/E –Yield –
About Nasus Pharma
Pharmaceutical Preparations, SIC 2834
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company that develops powder-based intranasal medications for acute and emergency medical situations. The company utilizes proprietary technology to deliver uniform spherical powder formulations into the nasal cavity for rapid drug absorption. Its primary product candidate is NS002, an intranasal epinephrine powder spray designed to treat severe allergic reactions. It also develops NS001, an intranasal naloxone candidate for opioid overdose, alongside preclinical programs exploring intranasal treatments for seizures, organophosphate poisoning, and vomiting. Because its product candidates remain in clinical development without regulatory approval, the company currently has no commercial customers, targeting patients who require immediate emergency care.
The company is incorporated and headquartered in Tel Aviv, Israel. It operates as a development-stage enterprise without commercial manufacturing facilities, relying on external contractors for drug supply, clinical operations, and laboratory materials. Its research footprint includes clinical trial operations in Canada, where it evaluates its investigational therapies in adult patient cohorts.
Summary of the business section of Nasus Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nasus Pharma Ltd
- Headquarters
- Tel Aviv - Yafo, L3
- Address
- 29 Harakevet St 6618003
- Phone
- 972 54-255-3956
- Website
- nasuspharma.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Brightman Almagor Zohar & Co, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- NSRX
- Exchange
- NYSE
- IPO date
- Aug 14, 2025
- Shares outstanding
- 9M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 2029039
- CUSIP
- M7071P109
- FIGI
- BBG01W00P7X8
- Share class FIGI
- BBG01W00P8Y5
- EIN
- 51-6022712
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brendan P. O'Grady | Chief Executive Officer, Director | – |
| Dan Benjamin Teleman | Chief Executive Officer, Director | 163,541 |
| Dalia Megiddo | Chief Development Officer, Director | 1,894,068 |
| Oren Elmaliah | Interim CFO | – |
| Eyal Rubin | Chief Financial Officer | – |
| Sharon Shacham | Director | – |
| David Silberman | Director | – |
| Isaac Israel | Director | – |
| Ronnie Hershman | Director | 1,338,463 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 14, 2025
- Offer price
- $8.00
- Exchange
- NYSE American
- First trading day
- Aug 13, 2025
- First-day close
- $8.25+3.1%
- Lock-up ends (est.)
- Feb 9, 2026
“Per Share Total Initial public offering price $ 8.00 $ 10,000,000 Underwriting discounts and commissions (1) $ 0.56 $ 700,000 Proceeds to us (before expenses) $ 7.44 $ 9,300,000 (1) Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offering”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 14, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 8, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?